ZOLMITRIPTAN 5MG TABLETS 6`S

KSh4,920.00

Migraine

Indicated for acute treatment of migraine with or without aura

2.5 mg PO/intranasally, initially, at onset of migraine

Dosing considerations

  • May increase dose to 5 mg; not to exceed 5 mg per single dose; individual response varies
  • May repeat dose if migraine has not resolved after 2 hr; not to exceed 10 mg/24 hr
  • Safety not established for tablets in the treatment of >3 migraines/30 days or >4 migraines/30 days for the intranasal formulation
  • Adverse Effects

    1-10%

    Dizziness (6-10%)

    Neck/throat/jaw pain (4-10%)

    Parasthesia (5-9%)

    Nausea (4-9%)

    Weakness (3-9%)

    Somnolence (5-8%)

    Warm/cold sensation (5-7%)

    Xerostomia (3-5%)

    Chest pain (2-4%)

    Diaphoresis (3%)

    Pain (2-3%)

    Dyspepsia (1-3%)

    Dysphagia (2%)

    Myasthenia (2%)

    Palpation (2%)

    Vertigo (2%)

    Hypoesthesia (1-2%)

    Myalgia (1-2%)

    <1%

    QT prolongation

    Bradycardia

    Tachycardia

    Thrombophlebitis

    Postural hypotension

    Hyperglycemia

    Alk phos increased

    Arthritis

    Twitching

    Myocardial infarction and artery vasospasm in patients with CAD risk factors

SKU: DP7123 Category:
0